CBAY News and Press, CymaBay Therapeutics Inc. From 09/11/20

Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis Self-reported pruritus improved at one year for patients in highest categories of baseline itch Selected for inclusion in the “Best of ILC” presentation Results ...

NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations w...

Introduction It’s closing in on almost 3-years since I first published my initial write-up on Viking Therapeutics ( VKTX ) back in Oct-2017. I’ve had plenty to say about the company since that time, publishing numerous other articles along the way, but more recently I’...

Fennec Pharmaceuticals (NASDAQ: FENC )   -31%  on FDA rejection of Pedmark application. More news on: Fennec Pharmaceuticals Inc., Mesoblast Limited, Genesis Healthcare, Inc., Stocks on the move, , Read more ...

Image source: The Motley Fool. CymaBay Therapeutics Inc.   (NASDAQ: CBAY) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading

CymaBay Therapeutics, Inc. (CBAY) Q2 2020 Results Earnings Conference Call August 10, 2020, 4:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - Chief Executive Officer Dr. Chuck McWherter - Chief Scientific Officer Klara Dickinson - Chief Regulator...

CymaBay Therapeutics (NASDAQ: CBAY ) : Q2 GAAP EPS of -$0.16 beats by $0.08 . More news on: CymaBay Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

FDA lifts all clinical holds on seladelpar Positive topline data announced from ENHANCE Company to reinitiate clinical development of seladelpar for patients with PBC Cash sufficient to fund current operating plan into 2022 Conference call and webcast today at 4:30 p.m. E...

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...